Inside Precision Medicine July 30, 2024
Yesterday, Boehringer Ingelheim announced it is acquiring Nerio Therapeutics, which has novel checkpoint inhibitors, for up to $1.3 billion. The pharma company aims to develop this program as a “potential key centerpiece component for its immuno-oncology portfolio,” according to a release. Nerio’s small molecules inhibit the proteins tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints and can activate the immune system to fight cancer cells.
The checkpoint inhibitor market is one of the world’s fastest growing and most lucrative. Almost a dozen such drugs have been approved in the last ten years. The global market was estimated to be worth over $40B in 2022 and is projected to reach almost $190B by 2032.
“Securing...
Today's Sponsors
Today's Sponsor